Abstract

Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call